Forte Biosciences, Inc. (FBRX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing FB102, a proprietary anti-CD122 monoclonal antibody for autoimmune indications. Key clinical milestones include the announcement of positive Phase 1b data for celiac disease in June 2025 and the subsequent initiation of a Phase 2 study in July 2025. The company is also advancing Phase 1b trials for non-segmental vitiligo and alopecia areata.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(11.2) million | $(26.9) million | $(19.9) million |
| Operating Expenses | $11.6 million | $27.7 million | $20.6 million |
| Cash & Equivalents (End of Period) | $106.1 million | $106.1 million | $24.5 million |
| Accumulated Deficit | $(180.9) million | $(180.9) million | $(138.5) million |
| Net Cash Used in Operating Activities | N/A | $(20.4) million | $(12.6) million |
Note: The company has no revenue and is not profitable. Margins are not applicable.
Material Changes vs. Prior Period
- Liquidity Surge: Cash and cash equivalents increased from $22.2 million at year-end 2024 to $106.1 million at June 30, 2025. This was driven by a public offering in June 2025 raising gross proceeds of $75.0 million and the redemption of $36.4 million in short-term investments.
- Expense Fluctuation:
- R&D Expenses: Increased significantly to $21.3 million for the six months ended June 2025 (vs. $10.1 million in 2024) due to manufacturing and clinical costs for Phase 1b trials in celiac disease and vitiligo.
- G&A Expenses: Decreased to $6.4 million for the six months ended June 2025 (vs. $10.5 million in 2024), primarily due to a $5.7 million reduction in legal and professional fees related to litigation settlements.
- Share Count: Outstanding shares increased from 6.4 million (Dec 31, 2024) to 12.3 million (June 30, 2025) following the June 2025 public offering and warrant exercises.
Guidance, Outlook, and Risks
- Clinical Outlook: Management expects topline data for the Phase 2 celiac study in 2026. Phase 1b vitiligo and alopecia areata data are also expected in 2026.
- Liquidity Runway: Management believes current cash resources ($106.1 million) are sufficient to fund operations for at least 12 months from the filing date.
- Capital Needs: The company anticipates continued losses and will require additional capital to complete clinical development. Future funding may come from equity/debt financings or strategic partnerships.
- Legal Proceedings:
- Insurance Dispute: Forte is litigating against its D&O insurance carriers (Wesco, Beazley, Palms) regarding coverage for prior shareholder actions (Camac Fund). The company seeks declaratory relief and damages.
- Settlements: Prior shareholder actions (Camac Fund) were settled in 2024 with payments totaling approximately $2.15 million.
- Regulatory/Tax: The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025, which includes accelerated tax deductions for research expenditures.
Investor Verification Checklist
- Verify the cash runway calculation given the increased burn rate associated with the new Phase 2 celiac trial.
- Review the status of the insurance litigation against Wesco/Beazley/Palms to assess potential recoveries for prior legal settlements.
- Monitor the dilution impact of the June 2025 offering and the 5.4 million pre-funded warrants currently outstanding.
- Confirm the timeline for the Phase 2 celiac topline data (expected 2026) and enrollment progress.
- Assess the impact of the OBBBA tax legislation on future effective tax rates and cash flows.